Thulium laser enucleation of the prostate plus thulium fiber laser therapy for benign prostatic hyperplasia combined with bladder stones

This work explored the feasibility, safety, and efficacy of using Thulium laser enucleation of the prostate (ThuLEP) and thulium fiber laser (TFL) on a single-energy platform to treat benign prostatic hyperplasia (BPH) combined with bladder stones (BS).Thirty-one patients with BPH complicated by BSs who underwent ThuLEP+TFL treatment at our institution between October 2020 and September 2022 were included in the observation group, while 31 patients undergoing transurethral enucleation of the prostate (TUEP) plus bladder lithotomy during the same period constituted the control group.Data collection involved assessing differences in International Prostate Symptom Score (IPSS), hemoglobin (Hb) levels, maximum urinary flow rate (Qmax), and quality of life (QOL) scores before and after surgery, along with collecting follow-up results.The results indicated that compared to the control group, patients in the observation group exhibited significantly lower surgical duration, postoperative decrease in Hb levels, duration of postoperative indwelling catheterization, and proportion of ASA II patients, with a higher proportion of ASA I patients (P<0.05).Additionally, compared to the control group, patients in the observation group had lower postoperative IPSS scores and higher levels of Hb, Qmax, and QOL scores (P<0.05).There was no significant difference in the postoperative stone clearance rate between the two groups (P>0.05);however, the postoperative length of hospital stay was significantly shorter in the observation group compared to the control group (P<0.05), with a significantly higher incidence of complications in the control group than in the observation group (P<0.05).In summary, ThuLEP + TFL surgery was safe and feasible in treating BPH + BS, relieved the symptoms, improved QOL of patients.